Figure S14 from ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

<p>Karpas1718 parental (A-B), SP53 (C-D), OCILY10 (C, E) and JEKO1-Cas9-ERBB4 (F-G) cells were exposed with DMSO (grey), idelalisib (red) or idelalisib + lapatinib (yellow) for 2-weeks. Expression levels of let-7c and miR-29c miRNAs (real-time PCR); and surface ERBB4 and intracellular HBEGF (both by FACS), were evaluated. RQ values calculated by the DDCt method. MFI for median fluorescence intensity. Expression levels of let-7c and miR-29c miRNAs (A), and surface ERBB4 and intracellular HBEGF (B) in Karpas1718 parental cells exposed with DMSO (grey), idelalisib (red) or idelalisib + lapatinib (yellow). Expression levels of let-7c and miR-29c miRNAs (C), and surface ERBB4 and intracellular HBEGF in SP53 (D) and OCILY10 (E) cells exposed with DMSO (grey), idelalisib (red) or idelalisib + lapatinib (yellow). Expression levels of surface ERBB4 and intracellular HBEGF in JEKO1-CNT (scramble sgRNA, F) and JEKO1-ERBB4 (sgRNA-ERBB4, G) cells exposed with DMSO (grey), idelalisib (red) or idelalisib + lapatinib (yellow). Data derived from two independent experiments; error bars represent standard deviation of the mean. * for p<0.05 from a t-test.</p>